HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2008
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/23448
- Acceso en línea:
- https://doi.org/10.1016/j.vaccine.2008.09.073
https://repository.urosario.edu.co/handle/10336/23448
- Palabra clave:
- Placebo
Silgard
Unclassified drug
Virus antibody
Wart virus vaccine
Adolescent
Adult
Antibody production
Antibody response
Article
Cancer immunization
Cancer prevention
Clinical trial
Controlled clinical trial
Controlled study
Double blind procedure
Drug efficacy
Female
Human
Infection prevention
Major clinical study
Phase 3 clinical trial
Priority journal
Randomized controlled trial
Uterine cervix carcinoma in situ
Wart virus
Adolescent
Condylomata acuminata
Female
Follow-up studies
Human papillomavirus 11
Human papillomavirus 16
Human papillomavirus 18
Human papillomavirus 6
Humans
Immunization schedule
Papillomavirus infections
Papillomavirus vaccines
Reverse transcriptase polymerase chain reaction
Vagina
Vaginal smears
Vulva
Young adult
Human papillomavirus
Humoral immunity
Immune memory
viral
Antibodies
- Rights
- License
- Abierto (Texto Completo)
id |
EDOCUR2_0da5ad858134d2d07fceda8bf0c9b85a |
---|---|
oai_identifier_str |
oai:repository.urosario.edu.co:10336/23448 |
network_acronym_str |
EDOCUR2 |
network_name_str |
Repositorio EdocUR - U. Rosario |
repository_id_str |
|
dc.title.spa.fl_str_mv |
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine |
title |
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine |
spellingShingle |
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine Placebo Silgard Unclassified drug Virus antibody Wart virus vaccine Adolescent Adult Antibody production Antibody response Article Cancer immunization Cancer prevention Clinical trial Controlled clinical trial Controlled study Double blind procedure Drug efficacy Female Human Infection prevention Major clinical study Phase 3 clinical trial Priority journal Randomized controlled trial Uterine cervix carcinoma in situ Wart virus Adolescent Condylomata acuminata Female Follow-up studies Human papillomavirus 11 Human papillomavirus 16 Human papillomavirus 18 Human papillomavirus 6 Humans Immunization schedule Papillomavirus infections Papillomavirus vaccines Reverse transcriptase polymerase chain reaction Vagina Vaginal smears Vulva Young adult Human papillomavirus Humoral immunity Immune memory viral Antibodies |
title_short |
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine |
title_full |
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine |
title_fullStr |
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine |
title_full_unstemmed |
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine |
title_sort |
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine |
dc.subject.keyword.spa.fl_str_mv |
Placebo Silgard Unclassified drug Virus antibody Wart virus vaccine Adolescent Adult Antibody production Antibody response Article Cancer immunization Cancer prevention Clinical trial Controlled clinical trial Controlled study Double blind procedure Drug efficacy Female Human Infection prevention Major clinical study Phase 3 clinical trial Priority journal Randomized controlled trial Uterine cervix carcinoma in situ Wart virus Adolescent Condylomata acuminata Female Follow-up studies Human papillomavirus 11 Human papillomavirus 16 Human papillomavirus 18 Human papillomavirus 6 Humans Immunization schedule Papillomavirus infections Papillomavirus vaccines Reverse transcriptase polymerase chain reaction Vagina Vaginal smears Vulva Young adult Human papillomavirus Humoral immunity Immune memory |
topic |
Placebo Silgard Unclassified drug Virus antibody Wart virus vaccine Adolescent Adult Antibody production Antibody response Article Cancer immunization Cancer prevention Clinical trial Controlled clinical trial Controlled study Double blind procedure Drug efficacy Female Human Infection prevention Major clinical study Phase 3 clinical trial Priority journal Randomized controlled trial Uterine cervix carcinoma in situ Wart virus Adolescent Condylomata acuminata Female Follow-up studies Human papillomavirus 11 Human papillomavirus 16 Human papillomavirus 18 Human papillomavirus 6 Humans Immunization schedule Papillomavirus infections Papillomavirus vaccines Reverse transcriptase polymerase chain reaction Vagina Vaginal smears Vulva Young adult Human papillomavirus Humoral immunity Immune memory viral Antibodies |
dc.subject.keyword.eng.fl_str_mv |
viral Antibodies |
description |
The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers. © 2008 Elsevier Ltd. All rights reserved. |
publishDate |
2008 |
dc.date.created.spa.fl_str_mv |
2008 |
dc.date.accessioned.none.fl_str_mv |
2020-05-26T00:02:06Z |
dc.date.available.none.fl_str_mv |
2020-05-26T00:02:06Z |
dc.type.eng.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.spa.spa.fl_str_mv |
Artículo |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1016/j.vaccine.2008.09.073 |
dc.identifier.issn.none.fl_str_mv |
0264410X 13588745 |
dc.identifier.uri.none.fl_str_mv |
https://repository.urosario.edu.co/handle/10336/23448 |
url |
https://doi.org/10.1016/j.vaccine.2008.09.073 https://repository.urosario.edu.co/handle/10336/23448 |
identifier_str_mv |
0264410X 13588745 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.citationEndPage.none.fl_str_mv |
6851 |
dc.relation.citationIssue.none.fl_str_mv |
No. 52 |
dc.relation.citationStartPage.none.fl_str_mv |
6844 |
dc.relation.citationTitle.none.fl_str_mv |
Vaccine |
dc.relation.citationVolume.none.fl_str_mv |
Vol. 26 |
dc.relation.ispartof.spa.fl_str_mv |
Vaccine, ISSN:0264410X, 13588745, Vol.26, No.52 (2008); pp. 6844-6851 |
dc.relation.uri.spa.fl_str_mv |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-56949087305&doi=10.1016%2fj.vaccine.2008.09.073&partnerID=40&md5=d26d764753441b12cfbb7a520688ce75 |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.acceso.spa.fl_str_mv |
Abierto (Texto Completo) |
rights_invalid_str_mv |
Abierto (Texto Completo) http://purl.org/coar/access_right/c_abf2 |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
institution |
Universidad del Rosario |
dc.source.instname.spa.fl_str_mv |
instname:Universidad del Rosario |
dc.source.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional EdocUR |
repository.name.fl_str_mv |
Repositorio institucional EdocUR |
repository.mail.fl_str_mv |
edocur@urosario.edu.co |
_version_ |
1828160550667812864 |
spelling |
a75a5428-1aaa-4075-a93f-98e319385bad-1ecccb0c4-cb95-4925-af5a-1ec964a2d76a-131b00978-d6b8-47c4-8a44-de2e315d2c8f-1aee4222e-774f-4684-9beb-4069b3db2716-1a016ed9a-4c40-4d3d-a538-a083f496ecc3-191d013f4-fece-4425-9068-a40f15ef934e-11dfc1d2b-911c-4aca-8dcd-77db5e092a42-1ac25aff2-3f7c-4ce9-98ef-b530755dbbc5-15094f39e-ccc9-48de-bede-b0481f534e8b-16b1eabf1-f5a4-4c7d-8d19-e055c1e32beb-1f10b7b3e-387f-4a90-94d3-de6c2ab8febf-1c59fe302-1d33-46e7-9505-6ccce05f4e7d-17f622cbd-6336-4a57-86d9-2da5efa57292-102fc9572-3dd6-40b2-80e7-bce5fbdd1eb0-1a65a15e3-6329-4786-a619-3a597770eff2-13c777468-016c-4688-b158-d4665174c3ee-158e46619-3a93-4b53-b4be-ac14b26bd165-13222d7b8-c070-4fc3-ae6c-6669826baf18-1cc491ce4-376e-4bd5-8962-5c82898472e1-1336e5d2c-2912-493d-a9fd-5d88fc6c566b-15889396a-284a-4576-a52c-e0d1f0c0f17b-162246fe4-4b85-4ccf-a7d3-7dc9ccaefe1c-140666f10-445b-4ccd-bae5-5381ba94f10d-15d07d84d-c1e8-4a2f-aed7-3bcaa13e0f79-182d160ec-619b-4e48-881b-b44d9e76fc63-1dcc194ad-98c2-4d71-8f0f-af895f661918-18a12e6d3-0263-47e3-8659-6e430f156601-1195cb5d0-9377-4dd6-b8fb-fdb31f36685a-19ea37233-65a2-464d-9e15-119e19583d07-1ce178588-a76d-43dd-aa4b-168721304f1b-1452b9c69-e9c0-4a80-abf3-d1bf4605f687-115d08f78-346e-493e-a24d-b07c151cb9fe-16bac68bd-ae22-45ec-b319-37d35ad26368-11474d0c8-dff7-4636-ba59-d342e91947ce-1dc4e5bce-11ba-4c28-8b4a-7aefe50942e4-123aa560d-194f-491c-a2bd-f00b038fe1f6-1e8151c88-7be0-4a39-bdee-a29f39c971b7-135dcdcbb-f667-458d-966c-e81ed018edd9-12020-05-26T00:02:06Z2020-05-26T00:02:06Z2008The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers. © 2008 Elsevier Ltd. All rights reserved.application/pdfhttps://doi.org/10.1016/j.vaccine.2008.09.0730264410X13588745https://repository.urosario.edu.co/handle/10336/23448eng6851No. 526844VaccineVol. 26Vaccine, ISSN:0264410X, 13588745, Vol.26, No.52 (2008); pp. 6844-6851https://www.scopus.com/inward/record.uri?eid=2-s2.0-56949087305&doi=10.1016%2fj.vaccine.2008.09.073&partnerID=40&md5=d26d764753441b12cfbb7a520688ce75Abierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURPlaceboSilgardUnclassified drugVirus antibodyWart virus vaccineAdolescentAdultAntibody productionAntibody responseArticleCancer immunizationCancer preventionClinical trialControlled clinical trialControlled studyDouble blind procedureDrug efficacyFemaleHumanInfection preventionMajor clinical studyPhase 3 clinical trialPriority journalRandomized controlled trialUterine cervix carcinoma in situWart virusAdolescentCondylomata acuminataFemaleFollow-up studiesHuman papillomavirus 11Human papillomavirus 16Human papillomavirus 18Human papillomavirus 6HumansImmunization schedulePapillomavirus infectionsPapillomavirus vaccinesReverse transcriptase polymerase chain reactionVaginaVaginal smearsVulvaYoung adultHuman papillomavirusHumoral immunityImmune memoryviralAntibodiesHPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccinearticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Joura, Elmar A.Kjaer, Susanne K.Wheeler, Cosette M.Sigurdsson, KristjánIversen, Ole-ErikHernandez-Avila, MauricioPerez, GonzaloBrown, Darron R.Koutsky, Laura A.Tay, Eng HseonGarcía, PatriciaAult, Kevin A.Garland, Suzanne M.Leodolter, SeppOlsson, Sven-EricTang, Grace W.K.Ferris, Daron G.Paavonen, JormaLehtinen, MattiSteben, MarcBosch, XavierDillner, JoakimKurman, Robert J.Majewski, SlawomirMuñoz, NubiaMyers, Evan R.Villa, Luisa L.Taddeo, Frank J.Roberts, ChristineTadesse, AmhaBryan, JanineLupinacci, Lisa C.Giacoletti, Katherine E.D.Lu, ShuangVuocolo, ScottHesley, Teresa M.Haupt, Richard M.Barr, Eliav10336/23448oai:repository.urosario.edu.co:10336/234482022-05-02 07:37:21.514609https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co |